Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04402632 · ClinicalTrials.gov registry record · NA
Embolization of the Middle Meningeal Artery With ONYX™ Liquid Embolic System for Subacute and Chronic Subdural Hematoma
A NA study, sponsored by Medtronic Neurovascular Clinical Affairs.
- Completed
- Registry status
- NA
- Development phase
- 600
- Enrollment target
NCT04402632 is a NA study that has completed, run by Medtronic Neurovascular Clinical Affairs. The registered enrollment target is 600 participants.
The verdict
NCT04402632, a NA study, has completed, sponsored by Medtronic Neurovascular Clinical Affairs.
- COMPLETED
- Registry status
- NA
- Development phase
- 600 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of embolization of the middle meningeal artery (MMA) using the Onyx™ Liquid Embolic System (LES) for treatment of symptomatic subacute or chronic subdural hematoma (SDH)
Interventions
- PROCEDURE Surgical Management
- DEVICE Onyx™ Liquid Embolic System (LES) Embolization
- OTHER Observation Only
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2020-10-27 |
| Est. Completion | 2025-04-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04402632
The ClinicalTrials.gov registry entry for NCT04402632 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Neurovascular Clinical Affairs, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Surgical Management is the first listed.
NCT04402632 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04402632 about?
NCT04402632 is a clinical study titled "Embolization of the Middle Meningeal Artery With ONYX™ Liquid Embolic System for Subacute and Chronic Subdural Hematoma". The purpose of this study is to evaluate the safety and efficacy of embolization of the middle meningeal artery (MMA) using the Onyx™ Liquid Embolic System (LES) for treatment of symptomatic subacute or chronic subdural hematoma (SDH)
What is the current status of trial NCT04402632?
This trial is currently completed. It is a NA study. The enrollment target is 600 participants. The study started on 2020-10-27. Estimated completion is 2025-04-03.
What interventions are being tested in trial NCT04402632?
The interventions under investigation include: Surgical Management (PROCEDURE), Onyx™ Liquid Embolic System (LES) Embolization (DEVICE), Observation Only (OTHER).
Who is sponsoring clinical trial NCT04402632?
This trial is sponsored by Medtronic Neurovascular Clinical Affairs, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.